Medpace Holdings, Inc. $MEDP Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 140,610 shares of the company’s stock after selling 7,391 shares during the quarter. Boston Trust Walden Corp owned about 0.49% of Medpace worth $67,520,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Root Financial Partners LLC increased its holdings in shares of Medpace by 34.1% in the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock valued at $59,000 after purchasing an additional 31 shares in the last quarter. Impact Partnership Wealth LLC increased its holdings in Medpace by 46.9% in the first quarter. Impact Partnership Wealth LLC now owns 1,426 shares of the company’s stock valued at $685,000 after buying an additional 455 shares in the last quarter. Brown Miller Wealth Management LLC increased its holdings in Medpace by 8.2% in the first quarter. Brown Miller Wealth Management LLC now owns 741 shares of the company’s stock valued at $356,000 after buying an additional 56 shares in the last quarter. 3Chopt Investment Partners LLC acquired a new stake in shares of Medpace during the 1st quarter valued at approximately $310,000. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Medpace during the 1st quarter valued at approximately $259,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $557.60 on Friday. The firm’s 50-day moving average is $452.89 and its two-hundred day moving average is $496.20. The company has a market capitalization of $15.93 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the company posted $3.67 EPS. The company’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on MEDP shares. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. BMO Capital Markets reduced their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Royal Bank Of Canada lowered their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, Robert W. Baird lowered their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $467.08.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.